Low-dose antibiotic spurs gut bacteria to make a longevity-linked compound in animals, study finds

Researchers report that small doses of the antibiotic cephaloridine can prompt certain gut bacteria to increase production of colanic acid, a microbial polysaccharide previously tied to longer lifespan in laboratory animals. In experiments, treated roundworms lived longer and mice showed shifts in cholesterol or insulin measures associated with aging, with the team arguing the approach works by acting in the gut rather than throughout the body.

A research team led by Meng C. Wang, a senior group leader at the Howard Hughes Medical Institute’s Janelia Research Campus, has reported a strategy for coaxing gut microbes to produce higher levels of colanic acid, a bacterial product that has been linked in prior work to longer life in animal models. (sciencedaily.com)

The study, published in PLOS Biology on November 11, 2025, found that exposing certain Escherichia coli strains to a low dose of the antibiotic cephaloridine led the bacteria to overproduce colanic acids. In the roundworm Caenorhabditis elegans, animals given cephaloridine lived longer, which the researchers linked to the increase in colanic acid. (sciencedaily.com)

The team also tested the approach in mice. According to the study’s summary and the journal report, oral low-dose cephaloridine triggered gene expression in gut bacteria tied to colanic acid biosynthesis and was associated with what the researchers described as an attenuation of age-related metabolic changes. The reported shifts included higher “good” cholesterol and lower “bad” cholesterol in male mice and reduced insulin levels in female mice. (sciencedaily.com)

A key premise of the approach is that cephaloridine can influence the gut microbiome without widespread effects in the rest of the body when administered orally. The researchers and the institutional summary describe cephaloridine as not being absorbed into the bloodstream when taken by mouth, which they argue could limit toxicity and other systemic side effects seen with many drugs. (sciencedaily.com)

In the paper, the authors report that the colanic-acid induction occurred through a mechanism that is independent of cephaloridine’s known antibiotic activity and involves the membrane-bound histidine kinase ZraS, suggesting the drug can act as a chemical signal to shift bacterial metabolism. (dx.doi.org)

The work was supported by the Howard Hughes Medical Institute, and the authors disclose that a patent application has been filed related to the research. (dx.doi.org)

Was die Leute sagen

Limited initial reactions on X include detailed neutral summaries of the study in a thread by a medical research account, positive commentary from longevity accounts portraying it as a counterintuitive advancement in microbiome-targeted longevity medicine, and one skeptical note on potential antibiotic resistance. Key points highlighted: low-dose cephaloridine boosts colanic acid production by gut bacteria, extending roundworm lifespan and improving mouse metabolic markers like cholesterol and insulin, with gut-confined action minimizing side effects.

Verwandte Artikel

Lab illustration of Paracoccus sanguinis bacteria from blood producing anti-aging indole metabolites that rejuvenate human skin cells, reducing stress and inflammation.
Bild generiert von KI

Blood-dwelling bacterium yields indole metabolites with anti-aging effects in skin cells

Von KI berichtet Bild generiert von KI Fakten geprüft

Researchers have identified indole metabolites from the human blood bacterium Paracoccus sanguinis that showed anti-aging activity in laboratory-grown human skin cells. The compounds reduced oxidative stress, inflammation and collagen-degrading activity in cell experiments, according to findings published in the Journal of Natural Products.

Researchers at the University of Cambridge report that 168 widely used industrial and agricultural chemicals slowed or stopped the growth of bacteria commonly found in a healthy human gut in laboratory experiments, raising questions about whether routine chemical exposure could affect the microbiome and, in some cases, antibiotic resistance.

Von KI berichtet

Researchers at Shandong University have modified the probiotic bacterium Escherichia coli Nissle 1917 to produce the anticancer drug Romidepsin directly in tumors. In mouse models of breast cancer, the engineered bacteria accumulated in tumors and released the drug. The findings were published on March 17 in PLOS Biology.

Researchers led by the University of Cambridge report that an uncultured group of gut bacteria known as CAG-170 appears more abundant in healthy people and is less common in several chronic diseases, based on analysis of more than 11,000 gut metagenomes from 39 countries.

Von KI berichtet Fakten geprüft

Researchers at Queen Mary University of London have found that rapalink-1, an experimental TOR inhibitor being investigated for cancer therapy, extends the lifespan of fission yeast. The study also uncovered a role for agmatinases in regulating the TOR pathway through a metabolic feedback loop, suggesting potential links between diet, gut microbes, and aging.

Researchers led by Helmholtz Munich report that some gut-dwelling bacteria — including strains not typically considered harmful — possess syringe-like molecular machinery that can deliver bacterial proteins into human cells, affecting immune and metabolic signaling. The work also links these bacterial “effector” genes to Crohn’s disease–associated microbiome patterns, though the authors say more studies are needed to determine how the mechanism influences disease.

Von KI berichtet

A Cold Spring Harbor Laboratory study demonstrated CAR T-cell therapy can reverse age-related intestinal decline in mice by targeting senescent cells. While promising, experts caution on safety risks, off-target effects, dosing, and costs for human use.

 

 

 

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen